Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Iterum TherapeuticsITRMF EV-to-EBIT is -0.93 as of Aug. 11, 2026. The stock has 4 warning signs investors should review. Among 372 Biotechnology companies, Iterum Therapeutics ranks worse than 268816.94% on this metric.
Iterum Therapeutics (OTCPK:ITRMF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Iterum Therapeutics's Enterprise Value for the quarter that ended in Sep. 2025 was $55.56 Mil.
Iterum Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iterum Therapeutics EV-to-EBIT Related Terms
Iterum Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Iterum Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Iterum Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iterum Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Iterum Therapeutics's EV-to-EBIT falls into.
Iterum Therapeutics's current Enterprise Value is $22.73 Mil.
Iterum Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iterum Therapeutics (ITRMF) has a EV-to-EBIT of -0.93 as of Aug. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Iterum Therapeutics and its competitors. According to the industry distribution chart, Iterum Therapeutics ranks #999999 out of 372 companies in the Biotechnology industry.
Is Iterum Therapeutics' EV-to-EBIT too high?
Iterum Therapeutics' current EV-to-EBIT is -0.93. Based on the distribution chart, Iterum Therapeutics ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Iterum Therapeutics' EV-to-EBIT compare to HEPA and MTNB?
According to the Biotechnology industry distribution chart, Iterum Therapeutics ranks #999999 out of 372 companies for EV-to-EBIT. This places Iterum Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.09, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Iterum Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iterum Therapeutics's current EV-to-EBIT is -0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current EV-to-EBIT of -0.93. The current EV-to-EBIT is -0.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current EV-to-EBIT is -0.93 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITRMF has been successfully added to your 
